Global Blood Therapeutics — Merger or Acquisition (August 2022)
11 slides from Global Blood Therapeutics's merger presentation, Aug 18, 2022
Slide 1: Breakthroughs that Change Patients' Lives
1 Confidential Breakthroughs that change patients’ lives Breakthroughs that Change Patients’ Lives 1
Slide 2: Pfizer Rare Disease Leadership Here Today
Confidential Internal Use Pfizer Rare Disease Leadership Here Today Chris Boshoff Rare Disease and Oncology Chief Development Officer Kevin Sullivan Incoming Global Specialty Care & US President Integration Sponsor Seng H. Cheng Rare Disease Chief Scientific Officer 2
Slide 3: Internal Medicine
3 Confidential Internal Medicine 3
Slide 4: Pfizer Purpose Blueprint
Confidential Internal Use Breakthroughs that change patients’ lives OUR PURPOSE OUR VALUES AND BEHAVIORS OUR BOLD MOVES Excellence Equity Joy Courage 1 Unleash the power of our people Deliver First-in- Class Science 2 Transform our go-to-market model 3 4 Win the Digital Race Lead the conversation 5
Slide 5: Our Reputation
5 Our Reputation TIM E 100 Most Influential Companies List #47 on Newsweek’s 2022 America’s Most Responsible Companies List #16 ranking on Bloomberg Brand Accelerator Ingenuity Top 100 List #34 ranking on Forbes America’s Best Employers For Diversity 2022 #4 ranking on Fortune’s annual World’s Most
Slide 6: Pfizer Biopharma Areas of Focus
6 Confidential Internal Medicine Hospital Inflammation and Immunology Internal Medicine Oncology Rare Disease Vaccines Pfizer Biopharma Areas of Focus Each focus area includes: Research Organization Development Organization Business Organization 6
Slide 7: Pfizer Rare Disease: For 30+ years, we have provided critical treatment options
7 Confidential Pfizer Rare Disease: For 30+ years, we have provided critical treatment options for patients with a range of rare diseases >1,000 Colleagues Across ~100 Countries We aspire to be the world’s leading innovator in rare disease by pioneering breakthrough science that has a profound impac
Slide 8: Poised to deliver a new generation of breakthrough medicines
We are poised to deliver a new generation of breakthrough medicines in areas of high unmet need Our deep pipeline has more than 8 investigational medicines in clinical development across a diverse range of therapeutic modalities, with more than five new molecular entities and three gene therapy prog
Slide 9: Pfizer Rare Disease: Breakthroughs
Internal Medicine ConCfoidnefindteianl tial 9 9 We aspire to be the world’s leading innovator in rare disease by pioneering breakthrough science that has a profound impact on the lives of underserved patient populations. Pfizer Rare Disease: Breakthroughs that change patients’ lives 9
Slide 10: Planning for the Integration Journey
Confidential 10 I nternal Medicine Minimize disruption to patients Ensure continuity of ongoing activities Respect for the GBT Team 1 2 3 Oindrila Pathani Integration Lead Matt Hefner Susan Dunne Business Development Integration Management Leads Kevin Matchett Portfolio & Program Management (PPM) Le
Slide 11: Thank You!
Confidential 11 Breakthr oughs that change patients’ lives Thank You! 11 Cautionary Statement Regarding Forward-Looking Statements This communication contains forward‑looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, related to Pfizer Inc. (“Pfizer”), Gl
Global Blood Therapeutics — Merger or Acquisition (August 2022) on 6ix